Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free GNCA Stock Alerts

Genocea Biosciences (GNCA) Competitors

Genocea Biosciences logo
Compare

GNCA vs. VRPX, SYRS, TRVN, NAVB, and PXMD

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Virpax Pharmaceuticals (VRPX), Syros Pharmaceuticals (SYRS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Genocea Biosciences' return on equity of -182.88% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Genocea Biosciences N/A -182.88%-62.76%

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Virpax Pharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Genocea Biosciences Neutral

Virpax Pharmaceuticals has a beta of -16.55, suggesting that its share price is 1,755% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Summary

Genocea Biosciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Genocea Biosciences Neutral

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Genocea Biosciences N/A -182.88%-62.76%

Summary

Genocea Biosciences beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Genocea Biosciences (NASDAQ:GNCA) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Genocea Biosciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Trevena$443K0.02-$40.29M-$47.04N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Trevena has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market.

Trevena's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Trevena N/A N/A -119.55%

In the previous week, Trevena's average media sentiment score of 0.37 beat Genocea Biosciences' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Genocea Biosciences Neutral
Trevena Neutral

Summary

Genocea Biosciences and Trevena tied by winning 5 of the 10 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Genocea Biosciences (NASDAQ:GNCA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PaxMedica has higher earnings, but lower revenue than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Genocea Biosciences Neutral

PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Genocea Biosciences N/A -182.88%-62.76%

Summary

Genocea Biosciences beats PaxMedica on 6 of the 9 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCA vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$12.47B$7.25B$13.16B
Dividend YieldN/A2.62%2.52%12.57%
P/E Ratio0.00792.33274.6925.81
Price / SalesN/A1,003.66681.05110.54
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6210.456.32
Net Income-$33.20M$2.81B$3.48B$359.77M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
VRPX
Virpax Pharmaceuticals
N/A$0.01
+11,000.0%		N/AN/A$14KN/AN/A7
SYRS
Syros Pharmaceuticals
N/A$0.00
-96.7%		N/A-86.7%$11K$386KN/A120
TRVN
Trevena
N/A$0.01
+2,700.0%		N/A-6.7%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCA) was last updated on 9/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel